THON

Thon Therapeutics is a biotechnology company pioneering the development of "off-the-shelf" human platelets through a scalable in vitro manufacturing platform. The company's technology aims to overcome the limitations of donor-dependent platelet supplies, such as short shelf life and contamination risks, by producing high-quality platelets from engineered megakaryocytes. Beyond simple transfusion, Thon is developing "designer platelets" capable of delivering therapeutic payloads directly to sites of injury or disease. This innovative approach has the potential to transform hematology, oncology, and regenerative medicine by providing a reliable and customizable source of cell-based therapies. The company is a spin-out from research conducted at Brigham and Women's Hospital and the University of Cambridge. Thon's platform leverages advanced bioengineering to replicate the bone marrow environment for efficient platelet production.